In addition, this medicine can be prescribed to prevent bone loss and reduce risk of fractures to cancer patients who are treated with hormone ablation therapy. In men with prostate cancer, socalled ‘androgeen deprivation therapy, i.e. chemical (with medicines) or surgical castration. In women with breast cancer this is going about the treatment with a aromatase inhibitor supplemental to the operation.
The active substance of Prolia is denosumab that the action of a protein (RANK ligand) inhibits.
The purpose of treatment is to reduce the risk of fractures by preventing bone loss and by treating osteoporosis.
Prolia is available in the Netherlands since March 2011 and is fully reimbursed.
Message leave amgen
